Vivos Therapeutics Inc (VVOS)

May 01, 2026

VVOS Forecast, Price Target & Analyst Ratings | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill

May 01, 2026

Apr 30, 2026

Vivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47 - MSN

Apr 30, 2026

Apr 29, 2026

Broadcom, Vivos Therapeutics and 3 stocks to watch heading into Monday - MSN

Apr 29, 2026

Apr 29, 2026

Vivos Therapeutics (NASDAQ: VVOS) registers 3.96M warrant-linked shares for resale - Stock Titan

Apr 29, 2026

Apr 29, 2026

VVOS Stock Chart | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill

Apr 29, 2026

Apr 24, 2026

VVOS Should I Buy - Intellectia AI

Apr 24, 2026

Apr 23, 2026

Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges - The Globe and Mail

Apr 23, 2026

Apr 22, 2026

Vivos Therapeutics receives Nasdaq notice for stockholders’ equity deficiency - Investing.com

Apr 22, 2026

Apr 22, 2026

Vivos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Apr 22, 2026

Apr 22, 2026

Equity shortfall puts Vivos Therapeutics (NASDAQ: VVOS) at Nasdaq delisting risk - Stock Titan

Apr 22, 2026

Apr 22, 2026

Qorvo To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga

Apr 22, 2026

Apr 21, 2026

Vivos Reports 16% Revenue Increase in 2025 Following Business Model Shift - Sleep Review

Apr 21, 2026

Apr 20, 2026

Vivos Therapeutics stock price target lowered to $2.50 by H.C. Wainwright - Investing.com Australia

Apr 20, 2026

Apr 18, 2026

New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM ESTShow #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Viv - ACCESS Newswire

Apr 18, 2026

Apr 18, 2026

Analysts Conflicted on These Healthcare Names: Vivos Therapeutics (VVOS), Certara (CERT) and Option Care Health (OPCH) - The Globe and Mail

Apr 18, 2026

Apr 17, 2026

H.C. Wainwright Maintains Vivos Therapeutics(VVOS.US) With Buy Rating, Cuts Target Price to $2.5 - 富途牛牛

Apr 17, 2026

Apr 17, 2026

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call Transcript - Insider Monkey

Apr 17, 2026

Apr 16, 2026

Vivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potential - MSN

Apr 16, 2026

Apr 16, 2026

Vivos Therapeutics (VVOS) Stock: Why Cash Position (Freefalls) 2026-04-16Popular Trader Picks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 16, 2026

Apr 16, 2026

Vivos Therapeutics Balances Growth Hopes With Cash Strain - TipRanks

Apr 16, 2026

Apr 16, 2026

Vivos Therapeutics Reports Full Year 2025 Financial Results - ADVFN

Apr 16, 2026

Apr 16, 2026

Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada

Apr 16, 2026

Apr 16, 2026

Vivos Therapeutics Reports 16% Revenue Growth in 2025, Advances Sleep Center Integration and Eyes Cash Flow Positive Operations - Minichart

Apr 16, 2026

Apr 15, 2026

Vivos Therapeutics Pivots to Medical-Provider Focused Model with Sleep Center of Nevada Acquisition to Expand Sleep Apnea Solutions 91 - Minichart

Apr 15, 2026

Apr 15, 2026

Earnings call transcript: vivos beats Q4 2025 earnings expectations - Investing.com UK

Apr 15, 2026

Apr 15, 2026

VVOS: 2025 revenue rose 16% as SCN integration fueled growth, with further expansion planned for 2026 - TradingView

Apr 15, 2026

Apr 15, 2026

Earnings Call Summary | Vivos Therapeutics(VVOS.US) Q4 2025 Earnings Conference - 富途牛牛

Apr 15, 2026

Apr 15, 2026

VVOS: 2025 revenue up 16% from SCN integration, with strong growth outlook as new model scales - TradingView

Apr 15, 2026

Apr 15, 2026

Earnings call transcript: vivos beats Q4 2025 earnings expectations By Investing.com - Investing.com India

Apr 15, 2026

Apr 15, 2026

Vivos Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat

Apr 15, 2026

Apr 15, 2026

Vivos Therapeutics (NASDAQ: VVOS) grows 2025 revenue as net loss widens - Stock Titan

Apr 15, 2026

Apr 15, 2026

Vivos Therapeutics 2025 10-K: $17.44M Revenue, $(2.07) EPS - TradingView

Apr 15, 2026

Apr 15, 2026

Vivos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 15, 2026

Apr 15, 2026

Vivos Therapeutics (NASDAQ: VVOS) details SCN deal and new sleep-center strategy - Stock Titan

Apr 15, 2026

Apr 15, 2026

Vivos grows on sleep apnea services, but operating loss hits $19.9M - Stock Titan

Apr 15, 2026

Apr 15, 2026

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results - National Today

Apr 15, 2026

Apr 15, 2026

Vivos Therapeutics, Inc. to Release Full Year 2025 Financial Results and Conduct Conference Call on April 15, 2026 - Quiver Quantitative

Apr 15, 2026

Apr 15, 2026

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call - The Manila Times

Apr 15, 2026

Apr 15, 2026

Vivos investors get 2025 results and strategy update at 5 p.m. ET - Stock Titan

Apr 15, 2026

Apr 15, 2026

Vivos Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Apr 15, 2026

Apr 14, 2026

Vivos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Apr 14, 2026

Apr 11, 2026

New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma (IGC), Vivos Therapeutics (VVOS), Acurx Pharmaceuticals (ACXP), and Equinox Gold (EQX) - Scott Coop

Apr 11, 2026

Apr 11, 2026

New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ - ACCESS Newswire

Apr 11, 2026